Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2022-002377-28
    Sponsor's Protocol Code Number:APHP210090
    National Competent Authority:France - ANSM
    Clinical Trial Type:EEA CTA
    Trial Status:Trial now transitioned
    Date on which this record was first entered in the EudraCT database:2022-07-25
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedFrance - ANSM
    A.2EudraCT number2022-002377-28
    A.3Full title of the trial
    Prognostic impact of early oseltamivir carboxylate underdosing in patients admitted to the ICU with severe influenza: a multicenter prospective cohort study
    Impact pronostique du sous-dosage précoce en oseltamivir carboxylate chez les patients admis en réanimation pour grippe grave : une étude de cohorte prospective multicentrique
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Prognostic impact of early oseltamivir carboxylate underdosing in patients admitted to the ICU with severe influenza: a multicenter prospective cohort study
    Impact pronostique du sous-dosage précoce en oseltamivir carboxylate chez les patients admis en réanimation pour grippe grave : une étude de cohorte prospective multicentrique
    A.3.2Name or abbreviated title of the trial where available
    OPTIFLU
    A.4.1Sponsor's protocol code numberAPHP210090
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAssistance Publique – Hôpitaux de Paris (AP-HP)
    B.1.3.4CountryFrance
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportGroupement Interrégional de Recherche Clinique et d’Innovation (GIRCI) d’Ile-de-France (PHRC-I 2020).
    B.4.2CountryFrance
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAP-HP - DRCI
    B.5.2Functional name of contact pointProject Manager
    B.5.3 Address:
    B.5.3.1Street Address1, avenue Claude Vellefaux - Hôpital Saint-Louis
    B.5.3.2Town/ cityParis
    B.5.3.3Post code75010
    B.5.3.4CountryFrance
    B.5.4Telephone number+330144841747
    B.5.5Fax number+330144 84 17 01
    B.5.6E-mailcandy.estevez@aphp.fr
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Tamiflu
    D.2.1.1.2Name of the Marketing Authorisation holderRoche Registration GmbH Emil-Barell-Strasse 1 79639 Grenzach-Wyhlen Allemagne
    D.2.1.2Country which granted the Marketing AuthorisationGermany
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Suspension for oral suspension
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPNasogastric use (Noncurrent)
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNOseltamivir
    D.3.9.1CAS number 196618-13-0
    D.3.9.4EV Substance CodeSUB03553MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number6
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name DOLIPRANE
    D.2.1.1.2Name of the Marketing Authorisation holderOPELLA HEALTHCARE FRANCE SAS
    D.2.1.2Country which granted the Marketing AuthorisationFrance
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Powder for oral solution
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPNasogastric use (Noncurrent)
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNparacetamol
    D.3.9.1CAS number 103-90-2
    D.3.9.4EV Substance CodeSUB09611MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number1000
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Adult patients admitted to the ICU for management of severe influenza infection requiring orotracheal intubation for invasive mechanical ventilation
    Patients adultes admis en réanimation pour la prise en charge d’une infection grippale sévère nécessitant une intubation orotrachéale pour ventilation mécanique invasive
    E.1.1.1Medical condition in easily understood language
    severe influenza infection requiring intubation for ventilation
    infection grippale sévère nécessitant une intubation pour ventilation
    E.1.1.2Therapeutic area Diseases [C] - Virus Diseases [C02]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level HLT
    E.1.2Classification code 10022005
    E.1.2Term Influenza viral infections
    E.1.2System Organ Class 100000004862
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To determine the prognostic impact of early plasma underdosing (measured at 48 hours of treatment) of oseltamivir carboxylate (OC) on early morbidity and mortality in patients hospitalized in the ICU for severe influenza infection
    Déterminer l’impact pronostique du sous-dosage plasmatique précoce (mesuré à la 48ème heure de traitement) en oseltamivir carboxylate (OC) sur la morbimortalité précoce des patients hospitalisés en réanimation pour infection grippale grave.
    E.2.2Secondary objectives of the trial
    1) To determine the diagnostic performance of the paracetamol absorption test for the early (H48) diagnosis of plasma OC underdosing
    2) To determine the prevalence of early (H48) plasma OC underdosing
    3) To determine the factors associated with early plasma OC underdosing
    4) Determine the relationship between early OC concentration and viral clearance
    5) Determine the relationship between early OC concentration and acquisition of an oseltamivir resistance mutation variant (H275Y) in the subgroup of patients with influenza A(H1N1)pdm2009 infection
    6) Study of the plasma pharmacokinetics of oseltamivir and determination of the prevalence of OC overdose
    1) Déterminer les performances diagnostiques du test d’absorption au paracétamol pour le diagnostic précoce (H48) du sous-dosage plasmatique en OC
    2) Déterminer la prévalence du sous-dosage plasmatique précoce (H48) en OC
    3) Déterminer les facteurs associés au sous-dosage plasmatique précoce en OC
    4) Déterminer la relation entre la concentration précoce d’OC et la clairance virale
    5) Déterminer la relation entre la concentration précoce d’OC et l’acquisition d’un variant portant la mutation de résistance à l’oseltamivir (H275Y) dans le sous-groupe des patients ayant une infection grippale A(H1N1)pdm2009
    6) Etude de la pharmacocinétique plasmatique d’oseltamivir et détermination de la prévalence du surdosage en OC
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    o Patients over 18 years of age
    o Confirmed severe influenza infection requiring resuscitation with tracheal intubation for invasive mechanical ventilation (influenza ARDS with or without bacterial co-infection, influenza-induced cardiorespiratory decompensation, influenza myocarditis)
    o Oseltamivir administered via a gastric tube and started less than 24 hours ago (i.e. maximum two doses administered)
    o Membership in a social security scheme, beneficiary or beneficiary's right (excluding AME)
    o Patient or, failing that, trusted person or, failing that, informed relative who has given written consent or inclusion according to emergency procedures.
    o Patients âgés de plus de 18 ans
    o Infection grippale grave confirmée nécessitant une prise en charge en réanimation avec intubation trachéale pour ventilation mécanique invasive (SDRA grippal avec coïnfection bactérienne ou non, décompensation cardio-respiratoire d’origine grippale, myocardite grippale)
    o Oseltamivir administré via une sonde gastrique et débuté depuis moins de 24 heures (soit maximum deux doses administrées)
    o Affiliation à un régime de sécurité sociale, bénéficiaire ou ayant droit (hors AME)
    o Patient ou à défaut personne de confiance ou à défaut proche informé et ayant donné son consentement écrit ou inclusion selon les procédures d’urgence.
    E.4Principal exclusion criteria
    o Pregnant or breastfeeding woman
    o Previous treatment with Zanamivir or other antiviral therapy active against the influenza virus for more than 24 hours
    o Co-infection with another respiratory virus (including SARS CoV-2)
    o Administration of medication via nasogastric tube is not possible
    o Severe hepatocellular insufficiency (TP<50%) or Child-Pugh C cirrhosis
    o Known allergy to paracetamol
    o Current participation in a therapeutic interventional trial (drug may interact with paracetamol or oseltamivir)
    o Patient receiving AME (Aide Médicale d'Etat)
    o Patient deprived of liberty or under legal protection (guardianship or curatorship)
    o For patients not included in an emergency situation: Inability, according to the investigator, to understand or refusal to sign the informed consent to participate in the study (non-French speaking patient).


    Secondary exclusion criteria
    In case of emergency inclusion:
    o Inability, in the opinion of the investigator, to understand (non-French speaking patient).
    o Refusal to sign the consent to continue by the relatives and/or the patient. The patient's participation stops at the date of refusal. The data collected up to this refusal may be used unless the patient and/or his relative objects. The patient will then be treated only in the context of care.
    o Femme enceinte ou allaitante
    o Traitement antérieur par Zanamivir ou autre traitement antiviral actif sur le virus de la grippe depuis plus de 24 heures
    o Co-infection par un autre virus respiratoire (notamment SARS CoV-2)
    o Administration de médicaments par sonde naso-gastrique impossible
    o Insuffisance hépatocellulaire sévère (TP<50%) ou cirrhose Child-Pugh C
    o Allergie au paracétamol connue
    o Participation en cours à un essai thérapeutique interventionnel (médicament pouvant interagir avec le paracétamol ou l’oseltamivir)
    o Patient bénéficiant de l’AME (Aide Médicale d’État)
    o Patient privé de liberté ou sous protection juridique (tutelle ou curatelle)
    o Pour les patients non inclus en situation d’urgence : Incapacité, selon l’investigateur, de comprendre ou refus de signer le consentement éclairé de participation à l’étude (patient non francophone).


    Critères d’exclusion secondaires
    En cas d’inclusion en urgence :
    o Incapacité, selon l’investigateur, de comprendre (patient non francophone).
    o Refus de signer le consentement de poursuite par les proches et/ou le patient. La participation du patient s’arrête à la date de refus. Les données recueillies jusqu’à cette refus pourront être utilisées sauf si le patient et/ou son proche s’y oppose. Le patient sera alors pris en charge uniquement dans le cadre du soin.

    E.5 End points
    E.5.1Primary end point(s)
    Number of days alive without invasive mechanical ventilation at D28. It will be compared between patients under-dosed in OC (active form of the drug, dosed here to measure its effective residual concentration) at 48 h of the initiation of treatment (under-dosage defined by a plasma residual concentration of OC lower than the laboratory standard) and patients not under-dosed.
    Nombre de jours vivants sans ventilation mécanique invasive à J28. Il sera comparé entre les patients sous-dosés en OC (forme active du médicament, dosée ici pour mesurer sa concentration résiduelle efficace) à 48 h de l’initiation du traitement (sous-dosage défini par une concentration résiduelle plasmatique d’OC inférieure à la norme du laboratoire) et les patients non sous-dosés.
    E.5.1.1Timepoint(s) of evaluation of this end point
    48th hour of treatment
    48ème heure de traitement par oseltamivir
    E.5.2Secondary end point(s)
    1) Diagnostic performance of the paracetamol absorption test (sensitivity, specificity, positive and negative predictive values, positive and negative likelihood ratios) performed at H48 for the diagnosis of plasma oseltamivir underdose. The reference test for this test (gold standard) is the plasma OC assay (underdosage defined by a residual plasma OC concentration below the laboratory standard). The test evaluated is the paracetamolemia assay.
    2) Prevalence of patients with plasma OC underdose
    3) Plasma OC underdose at H48 (dependent variable); the independent variables are the clinical and biological data present at admission, which will be studied as prognostic factors of OC underdose by uni and multivariate logistic regression models
    4) Viral clearance, calculated from nasopharyngeal viral load measurements performed at D1 (initial influenza diagnostic test) and D5. The association between viral clearance and plasma OC concentration at H48 will be assessed.
    5) Prevalence of acquisition of the H275Y oseltamivir resistance mutation (investigated by PCR and high throughput sequencing). The presence of H275Y mutation will be compared between patients with plasma OC underdose at H48 and the others
    6) Cmax and Residual measurements of OC and oseltamivir phosphate (OP, inactive prodrug) at D2, D3 and D5
    7) Mortality at D28 and D90 in patients under-dosed with OC at 48h of treatment initiation and in non-under-dosed patients.
    1) Performances diagnostiques du test d’absorption au paracétamol (sensibilité, spécificité, valeurs prédictives positive et négative, rapports de vraisemblance positif et négatif) réalisé à H48 pour le diagnostic du sous-dosage plasmatique en oseltamivir. L’examen de référence pour ce test (gold standard) est le dosage plasmatique d’OC (sous-dosage défini par une concentration résiduelle plasmatique d’OC inférieure à la norme du laboratoire). L’examen évalué est le dosage de la paracétamolémie.
    2) Prévalence des patients ayant un sous-dosage plasmatique d’OC
    3) Sous-dosage plasmatique en OC à H48 (variable dépendante) ; les variables indépendantes sont les données cliniques et biologiques présentes à l’admission, qui seront étudiées comme facteurs pronostiques de sous-dosage en OC par des modèles de régression logistique uni et multivariés
    4) Clairance virale, calculée à partir des mesures de la charge virale nasopharyngée réalisées à J1 (test diagnostique grippal initial) et J5. L’association entre la clairance virale et la concentration plasmatique en OC à H48 sera évaluée.
    5) Prévalence de l’acquisition de la mutation H275Y de résistance à l’oseltamivir (recherchée par PCR et séquençage à haut débit). La présence de mutation H275Y sera comparée entre les patients ayant un sous-dosage plasmatique en OC à H48 et les autres
    6) Mesures des Cmax et Crésiduelle d’OC et d’oseltamivir phosphate (OP, prodrogue inactive) à J2, J3 et J5
    7) Mortalité à J28 et J90 chez les patients sous-dosés en OC à 48h de l’initiation du traitement et les patients non sous-dosés
    E.5.2.1Timepoint(s) of evaluation of this end point
    48th hour of treatment
    D1 and D5
    D28 and D90
    48ème heure de traitement par oseltamivir
    J1, J5, J28, J90
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety No
    E.6.5Efficacy No
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) Yes
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned22
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS (physical or in phone)
    Dernière visite de suivi du dernier patient (physique si encore hospitalisé ou par téléphone)
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years
    E.8.9.1In the Member State concerned months27
    E.8.9.1In the Member State concerned days
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 75
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 80
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation Yes
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    Adult patients admitted to the ICU for management of severe influenza infection requiring orotracheal intubation for invasive mechanical ventilation
    Patients adultes admis en réanimation pour la prise en charge d’une infection grippale sévère nécessitant une intubation orotrachéale pour ventilation mécanique invasive
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state155
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2022-09-22
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2022-10-17
    P. End of Trial
    P.End of Trial StatusTrial now transitioned
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 02:49:37 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA